PT - JOURNAL ARTICLE AU - Tian, Suochen AU - Wu, Min AU - Chang, Zhenqin AU - Wang, Yunxia AU - Zhou, Guijie AU - Zhang, Wenming AU - Xing, Junmin AU - Tian, Hui AU - Zhang, Xihong AU - Zou, Xiuli AU - Zhang, Lina AU - Liu, Mingxin AU - Chen, Juan AU - Han, Jian AU - Ning, Kang AU - Chen, Shuangfeng AU - Wu, Tiejun TI - Epidemiological investigation and intergenerational clinical characteristics of 24 COVID-19 patients associated with supermarket cluster AID - 10.1101/2020.04.11.20058891 DP - 2020 Jan 01 TA - medRxiv PG - 2020.04.11.20058891 4099 - http://medrxiv.org/content/early/2020/04/15/2020.04.11.20058891.short 4100 - http://medrxiv.org/content/early/2020/04/15/2020.04.11.20058891.full AB - Objective To analyze the epidemiological and intergenerational clinical characteristics of COVID-19 patients associated with cluster, so as to understand the rules of the patients associated with cluster of this outbreak and provide help for the prevention and control of COVID-19.Methods All close contacts of the patient were screened since the first supermarket employee with COVID-19 was identified. A retrospective analysis was made on the epidemiological and clinical characteristics of the confirmed cases admitted to the designated hospitals for centralized treatment. The patients were divided into two groups according to the first generation (supermarket employees, group A) and the second or third generation (family members or friends of supermarket employees, group B), and the similarities and differences between the two groups were compared.Results A total of 24 COVID-19 patients were diagnosed, with an average age of 48 ±1.73 years. The mean duration from onset to release form quarantine was 21.04± 6.77 days, and the onset time was concentrated in 5-11 days after the first patient was diagnosed. Among all the patients, 23 patients were moderate, among which 7 patients (29.17%) were asymptomatic. Symptoms of symptomatic patients were cough (75.00%), low fever (62.50%), shortness of breath (41.67%), sore throat (25.00%), gastrointestinal symptoms (25.00%), fatigue (20.83%), etc. Biochemical examination on admission showed that the white blood cell count < 4.0×109/L (29.17%) and the lymphocyte count <1.1×109/L (58.33%). The lymphocyte count of 50.00% of the patients was ≤ 0.6 × 109/L. On admission, chest CT showed pneumonia (100%) with bilateral infiltration (75.00%). Treatment: antiviral drug (100%), Chinese medicine (100%), common oxygen therapy (45.83%). There were 11 cases in group A (first generation, 11 cases) and 13 cases in group B (second generation, 11 cases; third generation, 2 cases). In group B, there were more males, from onset to admission later, more patients had underlying diseases, and more patients were treated with albumin (P<0.05). However, there was no statistical difference between the two groups in other clinical indicators, including the duration from onset to release form quarantine(P>0.05). There was no improvement in granulocyte count in all patients, as well as in groups A and B, between admission and release from quarantine(P>0.05).Conclusion The clinical characteristics of COVID-19 patients associated with cluster were similar to those of other COVID-19 patients, but there were some special features. The severity of the disease was similar and there was intergenerational spread. There was no difference in clinical characteristics between generations. Asymptomatic infections occurred in a proportion of patients and could cause spread.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe haven't received any external funding.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWith the permission of the corresponding author, we can provide participant data,statistical analysis.